BOSTON SCIENTIFIC WILL ADD SCIMED'S 22% SHARE OF CORONARY ANGIOPLASTY MARKET WITH ACQUISITION OF THE FIRM UNDER $865 MIL. STOCK-SWAP DEAL
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will hold approximately one-fourth of the estimated $1.3 bil. worldwide coronary angioplasty market upon the completion of its acquisition of Scimed. On Nov. 8, the two companies announced a definitive agreement for a stock-swap merger valued at $865 mil.